S&P 500   3,959.72 (-0.10%)
DOW   33,689.04 (-0.27%)
QQQ   284.30 (+0.16%)
AAPL   144.00 (+0.95%)
MSFT   246.92 (-0.19%)
META   116.71 (+1.20%)
GOOGL   93.38 (-0.35%)
AMZN   89.61 (-0.82%)
TSLA   181.14 (+4.44%)
NVDA   173.15 (+0.85%)
NIO   12.79 (-4.62%)
BABA   91.71 (-2.61%)
AMD   69.53 (-1.33%)
T   19.20 (+0.42%)
MU   55.50 (+0.54%)
CGC   2.92 (-5.50%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.89 (-2.97%)
PYPL   73.94 (-0.38%)
PFE   51.93 (+0.29%)
NFLX   323.82 (+4.37%)
S&P 500   3,959.72 (-0.10%)
DOW   33,689.04 (-0.27%)
QQQ   284.30 (+0.16%)
AAPL   144.00 (+0.95%)
MSFT   246.92 (-0.19%)
META   116.71 (+1.20%)
GOOGL   93.38 (-0.35%)
AMZN   89.61 (-0.82%)
TSLA   181.14 (+4.44%)
NVDA   173.15 (+0.85%)
NIO   12.79 (-4.62%)
BABA   91.71 (-2.61%)
AMD   69.53 (-1.33%)
T   19.20 (+0.42%)
MU   55.50 (+0.54%)
CGC   2.92 (-5.50%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.89 (-2.97%)
PYPL   73.94 (-0.38%)
PFE   51.93 (+0.29%)
NFLX   323.82 (+4.37%)
S&P 500   3,959.72 (-0.10%)
DOW   33,689.04 (-0.27%)
QQQ   284.30 (+0.16%)
AAPL   144.00 (+0.95%)
MSFT   246.92 (-0.19%)
META   116.71 (+1.20%)
GOOGL   93.38 (-0.35%)
AMZN   89.61 (-0.82%)
TSLA   181.14 (+4.44%)
NVDA   173.15 (+0.85%)
NIO   12.79 (-4.62%)
BABA   91.71 (-2.61%)
AMD   69.53 (-1.33%)
T   19.20 (+0.42%)
MU   55.50 (+0.54%)
CGC   2.92 (-5.50%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.89 (-2.97%)
PYPL   73.94 (-0.38%)
PFE   51.93 (+0.29%)
NFLX   323.82 (+4.37%)
S&P 500   3,959.72 (-0.10%)
DOW   33,689.04 (-0.27%)
QQQ   284.30 (+0.16%)
AAPL   144.00 (+0.95%)
MSFT   246.92 (-0.19%)
META   116.71 (+1.20%)
GOOGL   93.38 (-0.35%)
AMZN   89.61 (-0.82%)
TSLA   181.14 (+4.44%)
NVDA   173.15 (+0.85%)
NIO   12.79 (-4.62%)
BABA   91.71 (-2.61%)
AMD   69.53 (-1.33%)
T   19.20 (+0.42%)
MU   55.50 (+0.54%)
CGC   2.92 (-5.50%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.89 (-2.97%)
PYPL   73.94 (-0.38%)
PFE   51.93 (+0.29%)
NFLX   323.82 (+4.37%)
NASDAQ:TRIB

Trinity Biotech - TRIB Stock Forecast, Price & News

$1.24
-0.04 (-3.13%)
(As of 12/9/2022 02:13 PM ET)
Add
Compare
Today's Range
$1.24
$1.24
50-Day Range
$1.07
$1.39
52-Week Range
$0.86
$1.99
Volume
100 shs
Average Volume
28,866 shs
Market Capitalization
$47.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Trinity Biotech MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Trinity Biotech in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.46) to ($0.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.36 out of 5 stars

Medical Sector

1007th out of 1,022 stocks

Diagnostic Substances Industry

15th out of 15 stocks

TRIB stock logo

About Trinity Biotech (NASDAQ:TRIB) Stock

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

TRIB Stock News Headlines

Trinity Biotech (NASDAQ:TRIB) Coverage Initiated at StockNews.com
TRIB Trinity Biotech plc
Trinity Biotech Announces Results of AGM
See More Headlines
Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

TRIB Company Calendar

Last Earnings
5/24/2021
Today
12/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRIB
Employees
543
Year Founded
1992

Profitability

Net Income
$880,000.00
Pretax Margin
-16.24%

Debt

Sales & Book Value

Annual Sales
$92.96 million
Cash Flow
$0.55 per share
Book Value
($0.02) per share

Miscellaneous

Free Float
34,983,000
Market Cap
$47.26 million
Optionable
Optionable
Beta
1.36

Social Links


Key Executives

  • Mr. John Gillard (Age 41)
    CFO, Company Sec. & Exec. Director
    Comp: $593k
  • Dr. James Walsh Ph.D. (Age 64)
    Exec. Director
    Comp: $20k
  • Mr. Aris Kekedjian (Age 55)
    CEO & Chairman
  • Mr. Simon Dunne (Age 48)
    Chief Accounting Officer
  • Ms. Eibhlin Kelly (Age 38)
    Chief Information Officer
  • Mr. Fernando Devia (Age 59)
    Exec. VP of Sales
  • Mr. Sanjiv Suri (Age 63)
    Sr. VP of Global Sales & GM of North America













TRIB Stock - Frequently Asked Questions

How have TRIB shares performed in 2022?

Trinity Biotech's stock was trading at $1.43 on January 1st, 2022. Since then, TRIB shares have decreased by 10.5% and is now trading at $1.28.
View the best growth stocks for 2022 here
.

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) posted its quarterly earnings results on Monday, May, 24th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.07 by $0.03. The firm earned $25.59 million during the quarter. Trinity Biotech had a negative trailing twelve-month return on equity of 345.70% and a negative net margin of 27.84%.

What guidance has Trinity Biotech issued on next quarter's earnings?

Trinity Biotech issued an update on its third quarter 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $19.00 million-$20.00 million.

What is Ronan O'Caoimh's approval rating as Trinity Biotech's CEO?

20 employees have rated Trinity Biotech Chief Executive Officer Ronan O'Caoimh on Glassdoor.com. Ronan O'Caoimh has an approval rating of 8% among the company's employees. This puts Ronan O'Caoimh in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD), Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Netflix (NFLX), Pfizer (PFE), QUALCOMM (QCOM), Energy Transfer (ET) and Exxon Mobil (XOM).

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Hunter Associates Investment Management LLC (4.72%) and Renaissance Technologies LLC (3.77%).

How do I buy shares of Trinity Biotech?

Shares of TRIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $1.28.

How much money does Trinity Biotech make?

Trinity Biotech (NASDAQ:TRIB) has a market capitalization of $48.78 million and generates $92.96 million in revenue each year. The company earns $880,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does Trinity Biotech have?

The company employs 543 workers across the globe.

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The official website for the company is www.trinitybiotech.com. The company can be reached via phone at (531) 276-9800, via email at kevin.tansley@trinitybiotech.com, or via fax at 353-1276-9888.

This page (NASDAQ:TRIB) was last updated on 12/9/2022 by MarketBeat.com Staff